Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma

Jeremy Abramson • 2 Jun 2015
ASCO 2015
Hodgkin Lymphoma Antibodies Brentuximab vedotin Dacarbazine Doxorubicin Vinblastine

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicenter Phase 2 study that is evaluating brentuximab vedotin, an antibody-drug conjugate, plus doxorubicin (adriamycin), vinblastine and dacarbazine (AVD) for the treatment of patients with non-bulky limited-stage classical Hodgkin lymphoma.

More from Jeremy Abramson

The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R/R DLBCL
6:35
The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R/R DLBCL
Jeremy Abramson • 14 Jun 2024
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
2:52
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
Jeremy Abramson • 12 Dec 2022
Emerging treatment strategies for patients with high-risk follicular lymphoma
2:05
Emerging treatment strategies for patients with high-risk follicular lymphoma
Jeremy Abramson • 12 Dec 2022
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
3:23
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
Jeremy Abramson • 12 Dec 2022

Related Videos

Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
1:42
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton • 6 Jul 2026
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
2:36
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton • 14 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals